Mental Health Clinics in Derby, VT Accepting Medicare
5 Mental Health Clinics found. Showing 1 - 5
 Pleasant Hill Behavioral Health Counselor - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 2040 Nelson Hill Rd, Derby, VT 05829 Phone: 623-215-5138 |
Nek Counseling And Consultation Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 3212 Us Route 5, Derby, VT 05829 Phone: 802-673-4907 Fax: 802-766-2275 |
Northeast Kingdom Human Services Inc Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 181 Crawford Road, Derby, VT 05829 Phone: 802-334-6744 Fax: 802-334-7340 |
Kingdom Therapeutics At Safe Haven Farm, Incorporated Clinic - Mental Health Medicare: Not Enrolled in Medicare Practice Location: 4095 Gore Rd, Derby, VT 05829 Phone: 802-673-6476 |
Northeast Kingdom Human Services, Inc Behavioral Analyst Medicare: Not Enrolled in Medicare Practice Location: 181 Crawford Road, Derby, VT 05829 Phone: 802-334-6744 Fax: 802-334-7340 |
News Archive
FDA grants orphan drug designation to ImmunoGen's lorvotuzumab mertansine for small-cell lung cancer
ImmunoGen, Inc., a biotechnology company that develops antibody-based targeted anticancer products, today announced that the US Food and Drug Administration (FDA) has granted orphan drug designation to its lorvotuzumab mertansine (formerly IMGN901) product candidate when used for the treatment of small-cell lung cancer (SCLC).
New study shows utility of Chronix Biomedical's serum DNA tests in MS
Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to treatment in multiple sclerosis. Chronix Biomedical uses proprietary technology to identify disease-specific genetic fingerprints based on the circulating DNA that is released into the bloodstream by damaged and dying cells.
Clinical utility and pharmacological action of MN-166 in treatment of MS
MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).
Study of genetic mutations could lead to optimized treatment plans for aplastic anemia patients
Scientists have identified a group of genetic mutations in patients with aplastic anemia, which likely will help doctors optimize treatment for this rare and deadly blood condition. The study, appearing in the New England Journal of Medicine, could lead to tailor-made treatment plans for aplastic anemia patients as part of the emerging precision medicine movement.
› Verified 1 days ago